28f73ee0-f218-4884-81c6-e6b4ba2fdccd
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 58
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.330
- INTERFERON_ALPHA_RESPONSE+0.310
- INTERFERON_GAMMA_RESPONSE+0.300
- ALLOGRAFT_REJECTION+0.290
- IL6_JAK_STAT3_SIGNALING+0.240
- PEROXISOME+0.200
- PANCREAS_BETA_CELLS+0.190
- INFLAMMATORY_RESPONSE+0.160
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.160
- IL2_STAT5_SIGNALING+0.150
Top 10 suppressed
- E2F_TARGETS-0.470
- G2M_CHECKPOINT-0.460
- HEDGEHOG_SIGNALING-0.440
- MITOTIC_SPINDLE-0.420
- ANGIOGENESIS-0.400
- MYC_TARGETS_V2-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- TGF_BETA_SIGNALING-0.330
- UNFOLDED_PROTEIN_RESPONSE-0.320
- MYC_TARGETS_V1-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG445 | — | — | 0.858 |
| 2 | TCGA-50-6597-01A-11R-1858-07 | — | cohortA1 | 0.839 |
| 3 | SRR33532817 | — | D | 0.834 |
| 4 | TCGA-91-A4BD-01A-11R-A24H-07 | — | cohortA1 | 0.833 |
| 5 | SRR2778078 | — | — | 0.830 |
| 6 | TCGA-GD-A76B-01A-11R-A32O-07 | — | — | 0.827 |
| 7 | SRR8518151 | — | D | 0.826 |
| 8 | 6d2b5716-f1e0-41af-bdc2-0efce35a3f26 | — | — | 0.825 |
| 9 | ERR2598330 | fetal | fetal | 0.825 |
| 10 | ERR2598274 | fetal | fetal | 0.822 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.030 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.020 | Remibrutinib | — uncovered |